Julie Vose, MD, MBA and Owen A. O’Connor, MD, PhD

In this video, “New Approaches for T-Cell Lymphomas”, Julie Vose, MD and Owen O’Connor, MD, PhD discuss research directions and unanswered questions.

Novel therapies used in relapsed/refractory T-cell lymphomas (e.g., brentuximab vedotin) are now being studied in induction regimens and in novel combinations. In PTCL, key questions include whether patients should be offered autologous peripheral stem cell transplantation in first complete response, and if relapse can be reduced by post-transplant maintenance therapy.

Share this story, choose your platform!